Learn More
OBJECTIVE Achieving therapeutic goals in multiple sclerosis (MS) requires strict adherence to treatment schedules. This retrospective study analyzed persistence with, and adherence to, fingolimod(More)
OBJECTIVE The cost-effectiveness of new oral disease-modifying therapies (DMTs) has not been modeled in highly active (HA) relapsing-remitting multiple sclerosis (RRMS) requiring escalation therapy.(More)
1. Multiple Sclerosis International Federation, 2013. Available from: http://www.msif.org/about-us/advocacy/atlas/ (Accessed 22 September 2015). 2. Derwenskus J. Mt Sinai J Med. 2011;78:161–175. 3.(More)
  • 1